Epstein Secrets

From: george church < > To: "Jeffrey E." <[email protected]> Subject: Re: value Date

From: george church < > To: "Jeffrey E." <[email protected]> Subject: Re: value Date: Fri, 11 Jul 2014 21:04:58 +0000 Jeffrey, Many thanks for your very encouraging words yesterday morning. This is already a super interesting experiment (even with $0 spent), since I am loo

m pests and invasive species. Lead by Kevin Esvelt. This will probably be in the news on July 17. Business model similar to the relationship between Amyris and the Gates Foundation for manufacturing anti-malaria drugs. 6) Making human genetic disease models in organoids and aging reversal using CRISPR

Sent from my iPad On Jul 13, 2014, at 12:40 PM, "jeffrey E." <[email protected]> wrote: 2? On Sun, Jul 1

To: George Church From: Jeffrey E. Sent Mon 8/11/2014 1:04:37 PM Subject: Re:

m pests and invasive species. Lead by Kevin Esvelt. This will probably be in the news on July 17. Business model similar to the relationship between Amyris and the Gates Foundation for manufacturing anti-malaria drugs. 6) Making human genetic disease models in organoids and aging reversal using CRISPR

at is the next step after that? --George From: "jeffrey E." <[email protected]> Date: Monday, August 11,

orts makes best progress first. --George From: "Jeffrey E." <jeevacation@gmail com> Date: Thursday, July

m pests and invasive species. Lead by Kevin Esvelt. This will probably be in the news on July 17. Business model similar to the relationship between Amyris and the Gates Foundation for manufacturing anti-malaria drugs. 6) Making human genetic disease models in organoids and aging reversal using CRISPR

To: Jeffrey E.Ueevacationiagmail.comi From: george church Se

e: widely popular or in style." --George From: "Jeffrey E." <[email protected]> Date: Monday, August 11,

m pests and invasive species. Lead by Kevin Esvelt. This will probably be in the news on July 17. Business model similar to the relationship between Amyris and the Gates Foundation for manufacturing anti-malaria drugs. 6) Making human genetic disease models in organoids and aging reversal using CRISPR

s Neivert 646 562 1370 [email protected] Jeffrey Osborne 646 562 1391 [email protected] C

e highlight two such agreements from the past few months below. Amyris / Undisclosed Partner (February 2019; Valued Up to $255MM) In February 2019, Amyris announced that it has signed an agreement for cannabinoid development, licensing, and commercialization in a partnership valued at up to $255MM (not

ulting in him crashing and falling off one of the vehicles. Complaint attached I Read full article » INTELLECTUAL PROPERTY Cannabinoid Maker Hits Amyris With $881M Trade Secrets Suit A cannabinoid manufacturer slapped biotech company Amyris with an $881 million trade secrets suit Thursday, alleging

l's attempt to keep her depositions from a settled defamation suit under seal, telling the Second Circuit that public interest outweighs the former Epstein associate's concerns that the transcripts could bias the sex trafficking case against her. 3 documents attached I Read full article COMPETITION St

& Gray EFTA00025527 --- PAGE BREAK --- One of Jeffrey Epstein's most outspoken accusers and a raft of media or

& Gray EFTA00025527 --- PAGE BREAK --- One of Jeffrey Epstein's most outspoken accusers and a raft of m

galactic version of the global village, bound together by planes and phones, you'd need to travel faster than light. 10 Contrary to popular belief, Emstein’s theory of rela- tivity does not rule that out completely. According to the theory, space and time are elastic; what we perceive as the force of gra

other crops. Solazyme is making oils and specialty fats to sell at high margins to cosmetics and food companies, as is would-be microbial fuel-maker Amyris. The industry for “advanced biofuels is literally mm its infancy,” con- cedes Jonathan Wolfson, Solazyme CEO. The allure of Primus’s technology 1s i